Skip to main content

Table 1 Patient’s baseline demographic and disease-related characteristics

From: Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer

Parameter

Cohort 1 (n = 50)

No. of pts. (%)

Cohort 2 (n = 50)

No. of pts. (%)

Age (years)

 31–40

01 (02)

02 (04)

 41–50

08 (16)

12 (24)

 51–60

18 (36)

11 (22)

 61–70

22 (44)

18 (36)

 71–80

01 (02)

07 (14)

Gender

 Male

45 (90)

43 (86)

 Female

05 (10)

07 (14)

Family history

 Present

12 (24)

09 (18)

 Absent

38 (76)

41 (82)

Anatomical site of tumor

 Oral cavity

28 (56)

33 (66)

 Oropharynx

08 (16)

07 (14)

 Nasopharynx

05 (10)

03 (06)

 Hypopharynx

07 (14)

04 (08)

 Larynx

02 (04)

03 (06)

ECOG PS

 0

28 (56)

26 (52)

 1

22 (44)

24 (48)

Site of recurrence

 Local recurrence

07 (14)

09 (18)

 Locoregional recurrence

11 (22)

12 (24)

 Metastasis

16 (32)

15 (30)

 Metastasis and local or regional recurrence

12 (24)

09 (18)

 Regional recurrence

04 (08)

05 (10)

Comorbidities

 Hypertension

16 (32)

17 (34)

 Diabetes mellitus

14 (28)

12 (24)

 Asthma

08 (16)

06 (12)

 Chronic obstructive pulmonary disease

02 (04)

04 (08)

 Gastric ulcer

09 (18)

11 (22)

 No comorbidities

01 (02)

00 (00)

  1. Eastern Cooperative Oncology Group (ECOG), performance status (PS)